Trials / Withdrawn

WithdrawnNCT03196921

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection

A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection

Status: Withdrawn
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Matinas BioPharma Nanotechnologies, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This will be an open label phase I/II prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection.

Conditions

Cryptococcal Infections

Interventions

Type	Name	Description
DRUG	Encochleated Amphotericin B	lipid-crystal nanoparticle formulation of amphotericin B; oral

Timeline

Start date: 2018-10-01
Primary completion: 2019-10-01
Completion: 2020-03-01
First posted: 2017-06-23
Last updated: 2019-03-08

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT03196921. Inclusion in this directory is not an endorsement.